A patient I worked with years ago described the thing that finally broke him. Not the DUI, not the lost job. It was standing in his own kitchen at 4 p.m., knowing exactly what alcohol had cost him, wanting to stop with everything he had, and reaching for the bottle anyway. He called it "the pull." He was not weak. He was fighting a brain that had been rewired to treat alcohol as more urgent than food, sleep, or his own children.
That pull now has a growing body of research behind it, and a new study suggests a way to turn its volume down. In late April, researchers at Copenhagen University Hospital, working with scientists at the U.S. National Institutes of Health, published a randomized controlled trial in The Lancet showing that semaglutide, the same GLP-1 medication sold as Ozempic and Wegovy for diabetes and weight loss, reduced heavy drinking in people with alcohol use disorder.
What the trial actually found
The team, led by Mette Kruse Klausen, M.D., and Anders Fink-Jensen, D.M.Sc., enrolled 108 treatment-seeking patients who had both alcohol use disorder and obesity. Everyone received standard cognitive behavioral therapy. On top of that, half got a weekly injection of semaglutide and half got a placebo, for 26 weeks.
The people on semaglutide had a 41.1% reduction in heavy drinking days, which was 13.7 percentage points larger than the drop in the placebo group. This was not just self-reported. Blood biomarkers of alcohol intake moved in the same direction, so the numbers held up when the researchers checked the patients' physiology against what they said.
The measure that got my attention most was the number needed to treat, which came out to 4.3. That means roughly one in every four or five patients benefited who would not have on placebo alone. Every medication currently approved for alcohol use disorder in the United States has a number needed to treat of 7 or higher. In plain terms, this drug helped more people than the tools we already reach for. George Koob and Nora Volkow, who direct the NIH institutes for alcohol and drug research and co-authored the study, both called the result encouraging while noting that longer and larger trials still need to confirm it.
Why a weight-loss drug touches drinking at all
Here is the part that matters if you want to understand your own brain or a loved one's. GLP-1 is a hormone your gut releases after you eat. It tells your brain you have had enough. For a long time we thought of that signal as being only about calories. It turns out the receptors that respond to it sit right inside the mesolimbic dopamine system, the same reward circuit that alcohol, opioids, and stimulants hijack.
When someone develops an addiction, that circuit does not light up more. It lights up less to ordinary life and more to the substance. This is the core of what researchers call reward deficiency: a dinner with family, a walk outside, a good night's sleep all start to feel flat, while the drug feels like the only thing that reaches the dial. That is why "just stop" fails so often. You are asking a person to choose a muted reward over an amplified one, using a self-control system the addiction has already worn down. I wrote more about how this circuitry works across nine different drugs in a recent look at the universal brain signature of addiction.
Semaglutide appears to work upstream of the pull. By acting on GLP-1 receptors in the reward pathway, it seems to lower how much salience the brain assigns to alcohol in the first place. Patients in earlier studies kept describing the same thing without being prompted: they simply thought about drinking less. The craving got quieter before they had to fight it. For a clinician who has spent three decades watching people white-knuckle their way through cravings, a medication that reduces the craving rather than the drinking is a different kind of tool.
What this does not mean
It would be a mistake to read this as a cure in a syringe. Notice that every person in the trial was also in cognitive behavioral therapy. The drug did not replace the work of recovery; it made the work more possible by quieting the biology that keeps sabotaging it. The people in the study also had obesity, and we do not yet know whether the effect is as strong in patients at a normal weight. The side effects, mostly nausea and other gut symptoms, were mild and faded, but they were real.
I raise these limits not to dampen the news but because false hope does as much damage in recovery as despair. What the trial gives us is a mechanism and a measurement, not a miracle. The mechanism tells us that addiction lives in the reward system, exactly where the biology says it does, and that we can reach that system with medicine.
What to take from this
If you or someone you love is fighting alcohol and has struggled with the medications already on the shelf, this is worth a specific, informed conversation with a physician, not a request for an off-label prescription based on a headline. GLP-1 medications carry their own risks and are not right for everyone. The point is that the treatment options are widening, and the old framing of drinking as a matter of character was wrong the whole time.
That framing is the reason so many people never ask for help. When we treat addiction as the brain disease it is, we get to do two things at once: reduce the shame that keeps people silent, and use the science that actually changes outcomes. Supporting the reward system with the right nutrition matters here too, which is part of why brain-directed supplementation through Action Potential Supplements sits alongside clinical care rather than in place of it. Real recovery has always needed both the biology and the human being. At Rescue From Rehab, that is the whole premise: treat the brain that got hijacked, and treat the person who never stopped trying.
The man in my kitchen story got better, years before any of this research existed. He did it the hard way. What moves me about a finding like this is not that it makes recovery easy. It is that the next person like him may not have to fight quite so alone against his own biology.